Dataset Information

In-depth proteome profiling of ovarian cancer FFPE tissues associated with therapeutic response to PARP inhibitor

ABSTRACT: The recent introduction of poly ADP-ribose polymerase (PARP) inhibitors has significantly improved the survival outcomes of ovarian cancer. This study aimed to identify protein biomarkers and signatures predicting therapeutic responses to PARP inhibitors in high-grade serous ovarian cancer (HGSOC). To identify prognostic biomarkers, we conducted an in-depth proteomic analysis on formalin-fixed paraffin-embedded (FFPE) cancer tissues obtained from 24 HGSOC patients who received PARP inhibitor maintenance therapy for platinum-sensitive recurrence. In total, 7825 proteins were quantified with the tandem mass tag (TMT) labelling method. There were 56 and 131 proteins significantly upregulated in the good and poor response groups, respectively.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Ovary Epithelium

DISEASE(S): Malignant Neoplasm Of Ovary

SUBMITTER: Dohyun Han

LAB HEAD: Dohyun Han

PROVIDER: PXD044703 | Pride | 2024-05-21

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20211220_OVARIAN_FFPE_TMT10_SET1_F1.msf	Msf
	20211220_OVARIAN_FFPE_TMT10_SET1_F1.pdResult	Other
	20211220_OVARIAN_FFPE_TMT10_SET1_F1.raw	Raw
	20211220_OVARIAN_FFPE_TMT10_SET1_F10.raw	Raw
	20211220_OVARIAN_FFPE_TMT10_SET1_F11.raw	Raw

Items per page:

1 - 5 of 75

Publications

Proteomic landscaping of high-grade serous ovarian carcinoma identifies stearoyl-CoA desaturase 5 as a potential predictive biomarker for poly(ADP-ribose) polymerase inhibitor response.

Kim Se Ik SI Kim Hyeyoon H Dan Kisoon K Park Hong-Beom HB Lee Cheol C Kim Hee Seung HS Chung Hyun Hoon HH Kim Jae-Weon JW Park Noh Hyun NH Han Dohyun D Lee Maria M

Clinical and translational medicine 20240501 5

PMID: 38720404

Similar Datasets

Project description:Alterations in glycosylation are seen in many types of cancer, including colorectal cancer (CRC). CRC is known to display glycosylation alterations. Glycans, the sugar moieties of glycoconjugates, are involved in many important functions relevant to cancer, such as cell signaling and adhesion, and may can be of value as biomarkers. In this study, we have used mass spectrometry to analyze the N-glycan profiles of 35 CRC tissue samples from patients with tumors in the right or left colon and 10 healthy tissue samples from non-CRC patients who underwent operations for other reasons. The tumor samples were divided into groups depending on tumor location (right or left colon) and stage (II or III), while the healthy samples were divided into right or left side of the colon. The levels of neutral and acidic N-glycan compositions and glycan classes were analyzed in a total of ten different groups. Surprisingly, there were no significant differences in glycan levels when all right- and left-sided CRC samples were compared, and few differences (such as in the abundance of the neutral N-glycan H3N5) were seen when the samples were divided according to both location and stage. Multiple significant differences were found in the levels of glycans and glycan classes when stage II and III samples were compared, and these glycans could be of value as candidates for new markers of cancer progression. In order to validate our findings, we analyzed healthy tissue samples from the right and left colon and found no significant differences in the levels of any of the glycans analyzed, confirming that our findings when comparing CRC samples from the right and left colon are not due to normal variations in the levels of glycans between the healthy right and left colon. Additionally, the levels of the acidic glycans H4N3F1P1, H5N4F1P1, and S1H5N4F1 were found to change in a cancer-specific but colon location-nonspecific manner, indicating that CRC affects glycan levels in similar ways, regardless of tumor location.